Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma
Document Type
Journal Article
Publication Date
6-25-2026
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
DOI
10.1158/1078-0432.CCR-25-4796
Abstract
PURPOSE: Patients with pathologically high-risk, HPV-negative HNSCC recur frequently despite adjuvant cisplatin-radiation therapy (CRT). As CRT can upregulate PD-1/L1 immune checkpoints, adding pembrolizumab may reverse treatment-induced immunosuppression. NRG-HN003 was a phase I trial assessing the safety and recommended phase II schedule of adjuvant pembrolizumab with CRT. Here, we report exploratory immune and genomic correlates of disease-free survival (DFS). PATIENTS AND METHODS: Thirty-four patients received pembrolizumab with CRT. PD-L1 expression was quantified by combined positive score (CPS) and spatial localization of PD-L1+ cells was assessed by multispectral imaging of baseline tumors. Disruptive TP53 mutations were evaluated by whole-exome sequencing. Soluble serum biomarkers were evaluated by Luminex, and circulating immune subsets were profiled by spectral flow cytometry at baseline and post-treatment. RESULTS: Patients with PD-L1 CPS≥20 showed numerically lower DFS than those with CPS<20; however, higher densities of PD-L1+ stromal cells were associated with more favorable outcomes. Disruptive TP53 mutations were not a significant negative prognostic factor. Among soluble markers at baseline, elevated serum arginase-1 was associated with inferior DFS, while higher levels of GM-CSF, IL-2 and nectin-2 were associated with more favorable outcomes. In circulating immune cells, higher baseline frequencies of CD8+ granzyme K+ T cells, as well as higher post-treatment frequencies of CD8+ CD39+ and regulatory CD4+ T cells, were associated with improved DFS. Increased effector and central memory T cell populations, especially post-treatment, also showed favorable associations with DFS. CONCLUSIONS: These findings highlight multiple potential immunologic correlates of pembrolizumab with CRT in high-risk HNSCC, supporting further evaluation and validation in larger, adequately powered trials.
APA Citation
Vujanovic, Lazar; Torres-Saavedra, Pedro; Tu, Fei; Uppaluri, Ravindra; Yao, Min; Chen, Josephine; Jordan, Richard; Geiger, Jessica L.; Jujjavarapu, Srinivas; Chakravarti, Arnab; Phan, Minh; Siddiqui, Farzan; Kulkarni, Aditi; Upadhyay, Pragati; Isett, Brian Robert; Sica, Gabriel L.; Reeder, Carly; Bao, Riyue; Chen, Jie; Joy, Marion; Freeman, Tanner; Harris, Jonathan; Le, Quynh-Thu; Bauman, Julie E.; and Ferris, Robert L., "Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma" (2026). GW Authored Works. Paper 9243.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/9243
Department
Medicine